Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patient-reported Outcome Claims On Kepivance Site Gets Full Throated FDA Response

This article was originally published in The Pink Sheet Daily

Executive Summary

SOBi’s oral mucositis treatment was studied in controlled trials that used patient-reported outcome measures, but their content validity has not been established, FDA’s Office of Prescription Drug Promotion says.

You may also be interested in...

Mystery Cake Ruins Party For EpiPen TV Ad

Mylan direct-to-consumer ad misleadingly suggested that as long as allergy sufferers have the product with them, they don’t need to do anything else to avoid anaphylactic shock, FDA says.

EPO Quality Of Life Claims Unsubstantiated, FDA Says, May Be Cut From Label

FDA is considering deleting patient-reported outcomes claims from epoetin alfa labeling, the agency announced during an advisory committee review of the anemia drug

Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says

Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts